ProCAncer-I in the 44th International Engineering in Medicine and Biology Conference in Glasgow
We are looking forward to participating in the 44th IEEE International Engineering in Medicine and Biology Conference in Glasgow! The Initiative will organize a miniSymposium under the session on Biomedical Imaging and Image Processing, with the title: Trustworthy AI...
ProCAncer-I in the IEEE-MeMeA Conference in Taormina
We are looking forward to participating it the upcoming IEEE-MeMeA Conference in Taormina! The 17th edition of IEEE International Symposium on Medical Measurements and Applications will take place in Giardini Naxos, Taormina in the metropolitan area of Messina,...
2nd ProCAncer-I Project Dissemination Event in Lisbon
We are really happy to be part of the "AI and Machine Learning in Cancer Imaging 3.0 – Enhancing Healthcare through AI” event on 30th June & 1st July 2023 in Lisbon, Portugal. The event is organised jointly by the Champalimaud Foundation and the International...
1st ProCAncer-I Project Dissemination Event in Vienna
We are really happy to announce that we will be present at the ECR Congress in Vienna on 13 - 17 of July 2022. During the congress, a special Session will take place on the 15th of July, presenting and discussing on the ProCAncer-I project with the title: Building...
Data sharing for a good cause – How the Data Governance Act (DGA) will help ProCAncer- I
The European Union is actively working on improving the digital environment for the benefit of all Europeans. Professor Tsiknakis took part in a recent feature in the EU Council site on how the EU protects users online, ensures cybersecurity and facilitates the...
Use Cases mapped along the prostate cancer management continuum
Nowadays, prostate cancer is highly curable if detected in its early stages. Indeed, when organ-confined at diagnosis, the five-year survival rate of prostate cancer is close to 100%. Unfortunately, current prostate cancer diagnostic pipeline has several limitations. Prostate specific antigen (PSA) has a low sensitivity and specificity.
Introducing FUTURE-AI: Best practices for trustworthy AI in medical imaging
ProCAncer -I Project is part of the five H2020 projects that share the same vision, principles and challenges. These projects are funded under the same Action Line: AI for Health Imaging (Call: H2020-SC1-FA-DTS-2019-1): CHAIMELEON (chaimeleon.eu), EuCanImage...
Our 3rd issue of the ProCAncer-I newsletter has been published!
Our third Summer Newsletter has been released! Read more here: 3nd Winter Newsleter Do not forget to subscribe for our next editions!
Our 2nd issue of the ProCAncer-I newsletter has been published!
Our second winter Newsletter has been released! Read more here: 2nd Winter Newsleter Do not forget to subscribe for our next editions!
System for detection of tumors based on magnetic resonance: prostate analysis (video)
How could AI improve prostate cancer diagnosis? This video from the research group of prof. Daniele Regge (coordinator of the clinical activities) explains AI application to prostate MRI.
Anonymous? Estimating the Risk of Re-identification Within the ProCAncer-I Health Data Sets
by Emily Johnson and Theresa Henne Age Weight PSA value Gleason Group 33 112,2 kg 7,9 ng/ml 3+4 Table 1. Is this data anonymous? Data sample of a fictional prostate cancer patient Imagine you stumble across the information given above - it may be part of...
Best Student Paper Award in the 21st IEEE International Conference on BioInformatics and BioEngineering
Our researchers received the Best Student Paper Award in Bioengineering category in the 21st IEEE International Conference on BioInformatics and BioEngineering that was held on October 25-27, 2021, at Kragujevac (Serbia). The award-winning paper is entitled: "A Deep...
